Abstract. The two forms of clathrin light chains (LCA and LCB) or clathrin-associated proteins (CAP~ and CAP2) have presented an immunochemical paradox. Biochemically similar, both possess two known functional parameters: binding the clathrin heavy chain and mediating the action of an uncoating ATPase. All previously reported anti-CAP mAbs, however, react specifically with only CAP~ (Brodsky, E M., 1985, 
T
HE cage structure enclosing clathrin-coated vesicles (CCVs) ~ self-assembles from triskelions composed of the three clathrin heavy chain and three clathrin light chain molecules (also called clathrin-associated proteins or CAPs [5, 9] ). Two forms of CAPs exist in cells of higher vertebrates: 33-kD (CAP2) and 36-kD (CAP1) forms are observed in tissues of neuronal origin, while analogous 28-and 30-kD forms are observed in other tissues (4) . The two forms isolated from brain tissue have several features in common, including the ability to bind calmodulin (9) and a single site on the clathrin heavy chain (14) , an essential role in mediating the action of an uncoating ATPase (11) , and resistance to denaturation by heating (9) , a property that facilitates their purification. The two forms are distinguishable by their migration rates during SDS PAGE, their slightly different isoelectric points (5, 10) , their differing immunological properties (6) , and by the enhanced ability of CAP2 to act as a substrate for phosphorylation under certain conditions (12) .
The production of mAbs reactive only with CAP1 (2, 6) provided evidence of the structural diversity of these two polypeptides. In this report, mAbs reactive with CAP2 and with both CAP1 and CAP2 are presented, and their charac-terization reveals that distinct epitopes are involved in mediating the functional parameters of CAPs.
Materials and Methods

Preparation of Hybridomas
Female BALB/c mice (6-8 wk of age) were initially immunized intraperitoneally with 100 ~tg of CAPs purified by heating at 100°C for 5 min as reported previously (9) and emulsified in complete Freund's adjuvant (day 74). Mice were boosted intrapetitoneally on day 32 with 100 I~g of antigen emulsified in incomplete Freund's adjuvant. Mice were boosted a final time with intraperitoneal and intravenous injections of 50 gg of antigen on days 4 and 3 before fusion on day 1.
Sp 2/0-Ag14 myeloma cells were cultured in RPMI 1640 supplemented with 15% fetal calf serum, 1 mM L-glutamine, 1 mM sodium pyruvate, 100 ~tM minimal essential medium nonessential amino acids, minimal essential medium vitamin solution, 100 ~tM 8-azaguanine, and antibiotics. Spleen cells from immunized animals were fused at a 5:1 ratio to Sp 2/0-Ag14 myeloma cells using deionized 44% polyethylene glycol 1,000 in RPMI 1640. Cells were plated into 96-well plates 24 h after fusion at a density of 104 myeloma cells per well (200 Ixl) and selected by adding 15 I.tg/ml hypoxanthine, 7.6 I~g/ml thymidine, and 0.18 lxg/ml aminopterin. This procedure usually yields at least one clone per well by the end of 10 d. Clones were passed to 1-ml wells before screening.
Hybridoma supernatants were screened by an ELISA. Briefly, antigens were coated onto polyvinyl chloride (PVC) plates (Linbro, Flow Laboratoties, Hamden, CT) at a concentration of 5 I.tg/ml in 5 mM Ttis, pH 8.0. Binding was performed at 37°C for 1 h followed by a 4°C incubation over-night. Free binding sites were saturated using 1% BSA in Tris-buffered saline (TBS), pH 7.5. Wells were incubated with culture supematants for 2 h at 37°C, washed three times with TBS containing 0.5% Tween 20. Wells were incubated with goat anti-mouse IgG/IgM conjugated to alkaline phosphatase (Boehringer Marmheim Biochemicals, Indianapolis, IN) for 1 h at 37°C, washed three times, then incubated for 1 h at 37"C with p-nitrophenyl phosphate (Sigma Chemical Co., St. Louis, MO). Absorbance at 405 nm was quantitated with a Titertek Multiskan microELISA reader.
Positive hybridomas were subcloned by limiting solution. Ascites fluid was generated in pristane (Aldrich Chemical Co., Milwaukee, WI) primed BALB/c mice. All mAbs reported here are IgG1; mAbs C-4E5 and C-10B2 have kappa light chains while C-6C1 and C-7H12 have lambda light chains. Antibodies were purified from ascites fluid by hydroxyapatite HPLC (BioRad Laboratories, Richmond, CA). Antibodies were coupled to cyanogen bromide-activated Sepharose 4B as described by the manufacturer (Pharmacia Fine Chemicals, Piscataway, NJ). mAb CVC-1 (6) was acquired from the American Type Culture Collection, Rockville, MD (TIB 135).
Sandwich ELISAs
HPLC-purified mAbs were cross-linked to alkaline phosphatase in the following manner. Antibody and alkaline phosphatase (bovine intestinal mucosa [Sigma Chemical Co.] were combined in PBS, pH 7.4, at 0.5 mg/ml each. The mixture was placed in a dialysis bag and dialyzed against a 500-fold excess volume of PBS containing 0.04% glutaraldehyde. After 8 h at 4°C, the bag was moved to 1,000-fold excess volume PBS without glutaraldehyde and dialyzed overnight at 4"C. Samples were run through a Bio-Gel P-200 column equilibrated with PBS containing 0.1% BSA. Colunm fractions were assayed directly by ELISA for CAP binding and enzyme activity.
PVC 96-well plates were incubated overnight at 4°C with 50 btg/rnl purified mAb in 5 mM Tris, pH 7.0. Plates were incubated the next day for 1 h at room temperature with 1% BSA in 20 mM normal TBS, pH 7.5. The plates were washed with TBS containing 0.5% Tween 20 (TBS-Tween) and incubated overnight at 4°C with 25 Ixg/ml CAPs in TBS-Tween. The next day the plates were washed twice with TBS-Tween and incubated for 2 h at 37°C with 5 tag/ml alkaline phosphatase-eonjugated mAbs in 1% BSA in TBS. The plates were washed twice with TBS-Tween and once with distilled H20. Reactions were developed with p-nitrophenyl phosphate in 100 mM glycine 1 mM MgCI2, 1 mM ZnCI2, pH 10.4. Color development was quantitated with a Titertek multiskan microELISA reader set at 405 nm.
Chymotryptic Digests
Chymotrypsin was dissolved first in 50 mM Tris, 10 mM MgCI2, pH 7.5, at 1 mg/mi, then diluted to 1.7 lag/ml in a 1 mg/ml CCV preparation in 100 mM morpholinnethanesulfonic acid buffer, pH 6.5. Digestions were performed for 30 s-1 h at room temperature before being stopped with 1 mM phenylmethylsulfonyl fluoride. Samples were then spun at 100,000 g in an airfuge and pellets and supernatants were dissolved in Laemmli sample buffer.
Radioiodination of CCVs and CAPs
CCVs and CAPs were radioiodinated using lactoperoxidase/glucose oxidase-coupled beads as described (Bio-Rad Laboratories). Before radioiodination, CCVs and CAPs were exhaustively dialyzed against pH 6.5 phosphate buffer. Subsequent to radioiodination, CCVs and CAPs were resuspended in 20 mM Hepes (Sigma Chemical Co.), pH 7.0, 1% BSA, 100 mM sodium chloride, 0.01% sodium azide, and were purified twice by Sepharose 4B column chromatography.
Phosphorylation of CAPS
Pbosphorylation of CCVs was conducted in 100 mM Tris, 10 mM MgCl2, 100 mM morpholinoethanesulfonic acid, pH 7.5. Reaction mixtures (100 ~l) contained 0.1 mg of CCVs, 20 I.tM ATP, and 1 I.tCi "t-32p-labeled ATE Some samples were supplemented by 50 ~g/ml poly-L-lysine 04 kD; Sigma Chemical Co.). Incubations were performed for 10 min at room temperature. Samples were heated at 100*C for 5 rain and spun at 100,000 g for I h before immunoprecipitation.
lmmunoprecipitation of CCVs and CAPs
Radioiodinated CCVs, CAPs, and phosphorylated CAPs were incubated with Sepharose 4B-coupled mAbs in Hepes, pH 7.0, containing 1% BSA, 100 mM sodium chloride, and 0.01% sodium azide. A typical experiment consisted of 50 I.tl of 5 % Sepharose 4B incubated with either 100 I.tg of unlabeled CAPs or 106 cpm of radioiodinated CAPs or CCVs. After incubating overnight at 4°C with agitation, the beads were pelleted briefly in a centrifuge (3200; Brinkmann Instruments Co., Westbury, NY), washed three times with 500 ~tl of 20 mM Hepes, pH 7.0, 1% BSA, then twice with 500 I.tl of 20 mM Hepes, pH Z0, containing 100 mM sodium chloride. Samples were dissociated in Laemmli sample buffer (0.1% SDS, 50 mM Tris, pH 6.5, 100 mM dithiothreitol, 10% glycerol) and counted.
Gel Electrophoresis and Immunoblotting
SDS PAGE was performed as described by Laemmli (7) . Gels were stained with Coomassie Brilliant Blue and/or dried and autoradiographed using a Cronex lightening plus intensifying screen and Cronex x-ray film (Dupont Co., Wilmington, DE).
Proteins were electrophoretically transferred to nitrocellulose using a transfer apparatus (Bio-Rad Laboratories) and the procedure described by the manufacturer. Nitrocellulose filters were fixed, then saturated with 0.1% BSA and 0.05% Tween 20 in TBS, pH 7.5. Filters were incubated at 4°C overnight with primary antibodies suspended in TBS, pH 7.5, containing 0.1% BSA and 0.05% Tween 20. Filters were washed three times with TBS containing 0.05% Tween, then incubated 1 h at 4°C with peroxidaseconjugated goat anti-mouse IgG/IgM (Boehringer Mannheim Biochemicals) diluted in TBS containing 0.1% BSA and 0.05% Tween 20. After three washes with TBS containing 0.05% Tween 20 and one wash with 20 mM Tris, 0.5 M NaCI, pH 7.5, reactive bands were visualized with 4-chloro-1-naphthol (Bio-Rad Laboratories) and 0.015% hydrogen peroxide.
Results
Four Epitopes of CAP2
Four unique mAbs to CAP2 were eventually generated from the fusion of immune BALB/c splenocytes to Sp2/0 myeloma cells. Two of them, mAbs C-7H12 and C-6C1, were produced from a BALB/c mouse immunized with CAPs isolated from CCVs by heating at 100°C for 5 min, while mAbs C-10B2 and C-4E5 were produced from a mouse immunized with whole clathrin. All four mAbs reacted with CAPs from both neuronal and nonneuronal sources (Figs. 1 and 2). To localize reactive sites of the mAbs, sandwich ELISAs were performed with purified mAbs coupled to alkaline phosphatase. PVC plates were coated with a purified mAb, incubated with cages, reassembled cages containing only CAP2 and purified CAPs (total protein concentrations: 1 mg/ml in 100 mM morpholinoethanesulfonic acid buffer, pH 6.5) were incubated with 1.7 Ig/ml chymotrypsin for various time periods, treated with phenylmethylsulfonyl fluoride, pelleted at 100,000 g in an airfuge (except the purified CAPs) and analyzed by SDS PAGE and immunoblotting with mAb C-7H12. (a) Coomassie stain of digested CCVs; (b) immunoblot of gel loaded as in a, using mAb C-7H12; (c) immunoblot using mAb C-7H12 of chymotryptically digested cages containing only CAP2; (d) immunoblot using mAb C-7H12 of chymotryptically digested cages containing both CAPt and CAP2; (e) immunoblot using mAb C-7H12 of chymotrypticaUy digested free CAPs. In d and e CAP~ was obscured by CAPz reactivity, a and b were run using 7-15% gradient gels, which allowed greater separation of the CAPS than the 8-16% gels used in c-e. a preparation of both CAPs, and subsequently incubated with a purified mAb coupled to alkaline phosphatase. The results of these experiments are summarized by the matrix in Table  I . All of the mAbs completely inhibited themselves in the assay but only variably inhibited each other. The mechanics of the sandwich ELISA prevent varying affinities of mAbs from affecting interpretation of the results. In other words, if the plate-bound antibody has a higher affinity for the same epitope as the competing antibody, the competing antibody will not bind and no reaction will be observed. If the opposite is true, the competing antibody will displace the bound CAP into solution and again no reaction will be observed in the solid phase. Therefore, the results of the sandwich ELISA matrix indicate that binding sites of mAbs C-7H12, C-6C1, C-10B2, and C-4E5 are distinct. The epitopes bound by C-7H12 and C-6C1 may be situated in the same domain of the CAP molecule and this would explain their partial inhibition in the sandwich ELISA. Similar results were obtained for mAbs C-10B2 and C-4E5, which completely inhibited themselves but only partially inhibited each other in the sandwich ELISA.
Close inspection of the sandwich ELISA matrix revealed that plate-bound mAbs C-7H12 and C-6C1 appear to slightly reduce binding by mAbs C-4E5 and C-10B2. The reciprocal experiments using plate-bound mAbs C-4E5 and C-10B2, however, did not reveal significantly reduced binding by C-6C1 or C-7H12. The inhibition may be attributed to binding of both CAPs by C-7H12 and C-6C1, which competitively reduces the binding of C-4E5 and C-10B2, which bind only CAP2. This effect is not observed in the reciprocal experiment inasmuch as C-7H12 and C-6C1 efficiently bind CAP2 sandwiched by either C-10B2 or C-4E5
Assigning mAb Binding Sites to Chymotryptic Fragments of CAPs
To characterize the reactive sites of each mAb on the CAP molecule, CCVs were chymotryptically digested and the vesicle-bound proteolytic fragments were isolated by centrifugation and subsequently analyzed by SDS PAGE and immunoblot. By varying the digestion times, CAP fragments were generated that were trimmed increasingly close to the heavy chain binding site. Immunoblotting experiments using these fragments and the anti-CAP mAbs facilitated construction of a cleavage map of the CAPs using the clathrin binding site as a reference point. Fig. 2 a shows chymotryptic fragments that were generated when CCVs were used as substrate. Fig. 2 b is an immunoblot of an identically loaded gel using mAb C-7H12. For convenience, we have divided the CAP fragments into two categories: fragments common to CCVs and reassembled cages (CFs) and unique fragments. The CFs consist of 30-kD (CF0, 18-kD ( C F 2 ) , and 15-kD ( C F 3 ) fragments. Previous experiments (8, 9) have shown that CF2 and C F 3 a r e pro- Purified mAbs were coated on PVC plates, incubated with CAPs, and subsequently incubated with alkaline phosphatase-conjugated mAbs. Reactivity was quantitated colorimetricaUy using p-nitrophenyl phosphate. Results represent the mean of three data points in a typical experiment. The concentration of plate-bound CAPs (last row) was adjusted stoichiometrically to 40% of the amount of plate-bound antibody. Coupled antibodies were titered to produce an OD at 405 nm of 1-1.5 after 1 h. A control value using an unrelated alkaline phosphatase-conjugated IgG1 murine mAb was determined for each row, and subtracted to give the reported results. + + + 66-100% of absorbance using PVC plate-bound CAPs. + + 65-32% of absorbance using PVC plate-bound CAPs. + 10-32% of absorbanee using PVC plate-bound CAPs.
-<10% of absorbance using PVC plate-bound CAPs. Purified mAbs, at various concentrations, were used and bound mAb was quantitated using an alkaline phosphatase-conjugated second antibody.
duced by chymotryptic digestion of either CCVs or reassembled clathrin cages. We show in Fig. 2 that CF1 can also be generated from either structure.
To determine which fragments are generated from CAPt and which are generated from CAPE, clathrin cages were stripped of CAPs with sodium isothiocyanate as described (14) , and reassociated with mAb C-4E5 afffinity-purified CAPE. The reassembled cages were digested with chymotrypsin as before and blotted with mAb C-7H12. As shown in Fig. 2 , c and d, CF~ and CF3 are produced by cages containing only CAPE; hence these fragments must be generated by proteolysis of CAPE, while CFE must be generated from CAP~. These results support the notion that CAP~ and CAP2 bind clathrin with structurally similar domains shared by both proteins. Interestingly, CVC-1 (6) also binds CFE (Fig. 1) , confirming its identity as a fragment of CAP1. CVC-1 (6) does not react with CAPE, CF3, or CFt, but it does react with clathrin-bound CAP~. These data indicate that CF2 contains at least two distinct epitopes: one is shared by CAP2 and appears to be involved in clathrin binding; the other is unique to CAP~.
Several CAP fragments are generated with molecular masses <10 kD using either CCVs or reassembled cages as substrates. The common fragments in this range are difficult to identify, although CCVs appear to produce a smaller set of fragments than reassembled cages. This implies that CAPs are less accessible in CCVs than they are in reassembled cages, which is not surprising considering the more complex structure of the vesicle. The small size of unique fragments generated from either reassembled cages or CCVs has led us to suggest that mAb C-7H12 binds an epitope involved in Figure 4 . Fraction of total radioiodinated CCVs or radioiodinated CAPs precipitated by anti-CAP mAbs coupled to Sepharose 4B. The mAbs used were at l@-fold excess over the amount needed to precipitate an equivalent mass of unlabeled CAPs. Iodination of free CAPs variably affected the efficiency of immunoprecipitation by each mAb.
clathrin heavy chain binding. Unless this epitope constitutes a linear string of amino acids, structural conservation of this region of the molecules may not be obvious from primary sequence analysis (3).
Anti-CAP reactivity was not detected in supernatants of chymotryptic digestion experiments using C-10B2, C-4E5, or anti-CAP1 mAb CVC-1 (6; data not shown). Either the released fragments are digested beyond recognition by these mAbs or the reactive epitopes span residues on both released and bound fragments. CAPs isolated by boiling and digested with chymotrypsin produce a plethora of new fragments in addition to CF~, CFE, and CF3 (Fig. 2 e) . Hence, binding by clathrin affords considerable protection against proteolysis by chymotrypsin.
Monoclonal Antibody 7H12 Reacts with the Clathrin-binding region of both CAPs
The immunoblot in Fig. 2 b shows that mAb C-7H12 reacts with both CAPs. Until now, all reported mAbs have reacted specifically with one of the CAPs (6). The existence of crossreactive epitopes may be predicted, however, from the biochemical characteristics of the proteins. In particular, both CAPs appear to bind a common site on the clathrin heavy chain (14) . This implies that the clathrin-binding regions of both CAPs share structural homology, and antibodies to this region of the molecules should cross-react with both forms. With these considerations in mind, an ELISA was used to determine the relative reactivity of each of the mAbs with free CAPs and clathrin-bound CAPs. Fig. 3 shows mAbs CVC-1 (6), C-4E5, C-10B2, C-6C1, and C-7H12 reacting with free CAPs. On the other hand, only mAbs CVC-1 (6), C-4E5, and C-10B2 react with the clathrin-bound CAPs present in purified preparations of triskelions, mAb C-6C1 reacts poorly with clathrin-bound CAPs, while mAb C-7H12 does not react with clathrin-bound CAPs. These results were obtained only when the clathrin-bound CAPs were pre-spun as cages or CCVs before coating on PVC plates. CAPs apparently dissociate from clathrin at a slow rate during storage at 4°C.
To document further the lack of reactivity of mAb C-7H12 with clathrin-bound CAPs, immunoprecipitation experiments were performed using radioiodinated CCVs and radioiodinated free CAPs. Purified mAbs C-7H12, C-10BE, CVC-1 (6), and C-4E5 covalently coupled to Sepharose 4B were used for these experiments. These mAbs precipitate radioiodinated free CAPs with varying efficiencies (Fig. 4) . mAb C-7H12, however, does not precipitate detectable counts of radioiodinated CCVs. This indicates that in the conformation present on the CCVs, CAPs are not recognized by mAb C-7H12, but are recognized by mAbs CVC-1, C-10B2, and C-4E5. These results differ from those reported recently (2) in which mAbs to CAP1 were only shown to be hindered from binding the clathrin-CAP complex. In total, our data suggest that mAb C-7H12 reacts directly with the clathrinbinding sites shared by both CAPs.
Mapping the CAP Phosphorylation Site to Accessible End of CAP2
A kinase activity recently has been associated with CAP2 (12, 13) . This activity was recently confirmed in another report and attributed to an endogenous CCV casein kinase II (1) . Although this activity is intensified by polybasic compounds such as polylysine or histone 1 (12) , phosphorylation can be detected in the absence of these compounds by immunoprecipitation and long-term automdiography (Kohtz, D. S., and S. Puszkin, unpublished results). A significant feature of this phosphorylation is its substrate preference for CAP2 (12) . Nevertheless, phosphorylation of CAP1 was detected in the presence of polylysine after radioimmune precipitation with anti-CAPl mAb CVC-1 (6) and long-term autoradiography (Fig. 5) . Whether phosphorylation sites are partially conserved between the two forms of CAP is unclear at present.
An ELISA was devised to determine how efficiently phosphorylated CAPs react with each of the mAbs in comparison to unphosphorylated CAPs. PVC plates were coated with unphosphorylated CAPs. The titer of purified mAb was adjusted in preliminary experiments to produce an optical density of 2 at 405 nm after 2 h of incubation (using a 1:1000 dilution of alkaline phosphatase-conjugated second antibody; Boehringer Mannheim Biochemicals). Purified mAbs at this dilution were preincubated with varying amounts of PVC plates were coated with unphosphorylated CAPs, then incubated with mAbs in the presence of the indicated amount of phosphorylated or unphosphorylated CAPs (phosphorylated/unphosphorylated). Binding was quantitated using an alkaline phosphatase-conjugated anti-mouse second antibody. Results represent the means of three values from a typical experiment. A control value using an unrelated IgG1 murine mAb was determined for each row, and subtracted to give the reported results.
either phosphorylated or unphosphorylated CAPs. These preparations were subsequently incubated with the PVC plate-bound CAPs, and bound antibody was quantitated with the alkaline phosphatase-conjugated anti-mouse second antibody. As shown in Table II , phosphorylated and unphosphorylated CAPs bind almost equally well to all of the mAbs. Phosphorylated CAPs do not appear to compete as well for mAb C-10B2 as unphosphorylated CAPs, although the difference is small. The similar affinities of phosphorylated and unphosphorylated CAPs for all the mAbs is also reflected in the efficiency of immunoprecipitation of phosphorylated CAPs. CAP2 was phosphorylated by the CCVassociated kinase activity in the presence of polylysine. The samples were heated, denatured proteins removed by centrifugation, and the CAPs precipitated with mAbs coupled to Sepharose 4B. Since the beads were coupled to equal amounts of purified antibody, we assumed that their specific binding activities were equivalent. The autoradiograph in Fig. 8 shows that mAbs C-10B2, C-4E5, and C-7H12 all precipitate phosphorylated CAPs in a quantitative manner. Interestingly, a doublet was precipitated by C-10B2. Using a limited concentration of CAPs and varying the proportion of phosphorylated CAP2 also does not appear to quantitatively affect the efficiency of CAP2 immunoprecipitation by any of the mAbs (Fig. 6 ).
To determine whether any of the mAbs reacted with epitopes relevant to the phosphorylation process, kinase inhibition experiments were performed (Fig. 7) . For this, mAbs at 3.5-fold molar excess to CAP2 were incubated with CCVs in phosphorylation buffer overnight at 4°C. Polylysine and gamma radiolabeled ATP were added and the reactions were stopped at various time points with EDTA. Samples were heated to 100°C for 10 rain and pelleted. The supernatants were analyzed by SDS PAGE and autoradiography. None of the mAbs inhibited phosphorylation of casein by the endogenous CCV casein kinase II (data not shown). Both mAbs C-4E5 and C-10B2 inhibited phosphorylation of CAP2 for as long as 5 min after the addition of ATP. The inhibition profiles of these mAbs appear to differ slightly. CCVs preincubated with C-10B2 rapidly acquire a small amount of Figure 6 . Relative efficiency of immunoprecipitation of phosphorylated and unphosphorylated CAPs by mAbs C-10B2, C-4E5, and C-7H12. A limiting titer of coupled antibody was used to precipitate a total of 20 Ixg of CAP2. The various amounts of phosphorylated CAP2 in the total amount are indicated in micrograms. Were phosphorylated CAP2 precipitated less efficiently than unphosphorylated CAP2, the total precipitated protein would be reduced as the proportion of phosphorylated CAP2 increased. The lower molecular mass bands are antibody light chains, which apparently do not couple efficiently and are released in Laemmli sample buffer containing dithiothreitol. Arrow indicates CAPx precipitated by mAb C-10B2.
CAP2-bound phosphate before being completely inhibited, while CCVs preincubated with C-4E5 slowly but progressively acquire CAP2-bound phosphate. The pattern of inhibition produced by mAb C-4E5 could be interpreted as less complete than that produced by mAb C-10B2. This would result from differences in affinity between the two mAbs, or differences in the proximity of the antigenic sites to the phosphorylation site. Alternatively, since it has been suggested that CAP2 contains more than one phosphorylation site (12) , the antibodies may be inhibiting the phosphorylation of different residues. Further experiments are in progress to determine which of these possibilities is valid (Kohtz, D. S., W. J. Schook, and S. Puszkin, manuscript in preparation).
A 32-kD Phosphoprotein Cross-reacts with Anti-CAPz mAb C-10B2
Curiously, mAb C-10B2 coprecipitates another heat-stable, 32-kD phosphoprotein from the CCV preparation. As indicated by the open arrow on the autoradiography in Fig. 8 , the coprecipitated phosphoprotein migrates immediately below the phosphorylated CAPE. This phosphoprotein apparently competes very effectively with CAP2 for mAb C-10B2, since it is not detectable in preparations of total CAPs (e.g., Fig. 5,   lanes A and A' ). In C-10B2 precipitate, the 32-kD phosphoprotein is substantially enriched, indicating an affinity for mAb C-10B2 at least as high as that of CAP2; this is apparent in both the autoradiograph in Fig. 8 and in the Coomassie stain in Fig. 6 (indicated by arrow) .
The 32-kD protein does not react with mAbs reactive with CAP~ nor with mAbs reactive with DARPP 32 (kindly provided by Dr. P. Greengard, Rockefeller University, New York). Also, it only reacts with one of the four mAbs recognizing CAPE (although traces may be present in mAb C-4E5 precipitates, not shown), implying that it is not a proteolytic fragment of this protein. We have tentatively labeled this phosphoprotein CAPx (or LCx), and are presently determining whether it is a CCV component or a soluble contaminant of our preparations. Its stability during heat denaturation (the vesicles are heated and centrifuged before precipitation), phosphorylation properties (it is phosphorylated in the presence of polylysine), and cross-reactivity with an anti-CAP2 mAb (C-10B2) indicate that it may be structurally related to CAP2.
Discussion
The characterization of mAbs to CAPs by our laboratory and others (2, 6) has revealed considerable structural diversity between the two forms (CAPI and CAP2). The functional significance of this diversity is probably relevant to the evolution of higher organisms, since yeast appear to possess only one form of CAP. At present, the explicit functions associated with this diversity have evaded elucidation. Instead, two properties mediated equally well by both forms of CAPs have been described: (a) an ATP-dependent uncoating enzyme works by initially binding to either of the CAP molecules (11) , and (b) a single site on the clathrin heavy chain binds equally well to either form of CAP (14) . Hence, mAbs that distinguish the two forms of CAPs would not be as likely to recognize epitopes involved in these conserved functions as mAbs reacting with both CAPs.
In this report, two mAbs (C-6C1 and C-7H12) are presented that react with epitopes shared by both CAPs. The term "conserved domain" may be used to describe the structural region of the CAPs reactive with these mAbs. The significance of the epitope recognized by C-6C1 has not been detailed, although chymotryptic mapping experiments re- vealed that it is near the clathrin-binding region of the CAPs. The mAb C-7H12 appears to react with an epitope directly on the clathrin-binding domain as evidenced by chymotryptic mapping, ELISAs using clathrin-bound CAPs and free CAPs, and immunoprecipitation experiments using radioiodinated CCVs and CAPs. Sandwich ELISAs indicate that, despite their proximity, the epitopes recognized by mAbs C-6C1 and C-7H12 are distinct.
We describe elsewhere two mAbs (C-10B2 and C-4E5) reactive specifically with CAP2 (Kohtz, D. S., J. D. Kohtz, W. J. Schook, and S. Puszkin, manuscript submitted for publication). Sandwich ELISAs indicate that mAbs C-10B2, C-4E5, C-7H12 and C-6C1 react with distinct epitopes on CAPE. As may be inferred from the degree of sterically induced inhibition observed in these assays, mAbs C-10B2 and C-4E5 appear to react with different epitopes in the same region of CAPE. As judged by its sensitivity to chymotryptic digestion, this region of CAPE is on an accessible end of the molecule. The term "nonconserved domain" may be used to refer to this accessible edge of the CAP2 and its putative counterpart on CAPI.
Two kinase activities are associated with CCVs. The first is CaE+/calmodulin -and cAMP-independent, and uses the 50-kD assembly complex polypeptide as a substrate; the second is accentuated by the presence of polybasic compounds and uses CAPE as a substrate. Direct inhibition experiments indicate that mAb C-10B2 and C-4E5 react with an epitope relevant to the phosphorylation process. In particular, C-4E5 inhibits phosphorylation better in the short run while C-lOB2 inhibits better in the long run. Inhibition of CAPE phosphorylation by these mAbs could be produced by several mechanisms: steric interference of the bound antibody and the enzyme; allosteric structural alterations produced in CAPs by bound antibody; direct competition for the enzyme binding site by the antibody; and, if it is distinct from the enzyme-binding site, direct blocking of the phosphorylation site by bound antibody. Further work is necessary to determine the mechanisms responsible for inhibition of CAPE phosphorylation by each mAb.
Immunoprecipitation experiments using mAb C-10B2 revealed a cross-reactive phosphoprotein with a molecular mass of 32 kD. We referred to this phosphoprotein as CAPx or LCx, since it coprecipitates with CAPE. This polypeptide is not coprecipitated by C-4E5, CVC-1 (6), C-7H12, or C-6C1, indicating that it is not a CAP fragment. Since CAPx is a phosphoprotein and C-10B2 does inhibit CAP2 phosphorylation, it appears that C-10B2 cross-reacts with the phosphorylated epitopes on both polypeptides. Similarities between the polypeptides suggest that it is a member of the CAP family. In particular, CAPx is heat stable, it can be isolated from CCV preparations, and it is phosphorylated under the same conditions as CAPE. When a CAPx-specific antibody is produced it may be possible to ascertain if the polypeptide is an integral vesicle protein.
Immunoprecipitation experiments using C-4E5 and CVC-1 (6) revealed two other properties of CAP phosphorylation. CAPE is phosphorylated in the absence of effectors, but to a considerably lesser degree; and CAP1 is also phosphoryluted in the presence of polylysine, but not to the same extent as CAPE. The latter observation implies that the phosphorylation process is not absolutely specific for CAPE, and in the presence of other mediators or enzymes, CAPl may be equally well phosphorylated. Alternatively, Usami et al. (13) , have indicated that CAPE bears three sites of phosphorylation; CAP~ may have conserved only a fraction of these sites. Further work should elucidate the physiological significance of each site of phosphorylation and their distribution on each CAE
